Arena Pharmaceuticals Inc. (ARNA): Today's Featured Drugs Loser

Arena Pharmaceuticals ( ARNA) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.7%. By the end of trading, Arena Pharmaceuticals fell 6 cents (-0.5%) to $11.05 on average volume. Throughout the day, 22.1 million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 25 million shares. The stock ranged in price between $10.62-$11.52 after having opened the day at $11.01 as compared to the previous trading day's close of $11.11. Other company's within the Drugs industry that declined today were: Savient Pharmaceuticals ( SVNT), down 15.5%, Rexahn Pharmaceuticals ( RNN), down 13.5%, Tekmira Pharmaceuticals Corporation ( TKMR), down 13.4%, and Biosante Pharmaceuticals ( BPAX), down 12.9%.

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $2.2 billion and is part of the health care sector. Shares are up 497.9% year to date as of the close of trading on Monday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and six rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity.

On the positive front, StemCells ( STEM), up 106.9%, Peregrine Pharmaceuticals ( PPHM), up 26.4%, Allos Therapeutics ( ALTH), up 21.7%, and Hemispherx Biopharma ( HEB), up 20.5%, were all gainers within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

Allergan, USG Corp, Arena Pharmaceuticals: 'Mad Money' Lightning Round

These Stocks Have Changed Direction

These Stocks Have Changed Direction

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case